期刊
ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING
卷 11, 期 1, 页码 231-247出版社
WILEY
DOI: 10.1016/j.dadm.2018.12.003
关键词
Alzheimer's Disease; Mild cognitive impairment; Outcomes; Systematic review; Qualitative; Quantitative; Quality of life; Memory; Activities of daily living; Autonomy; Burden; Patients; Caregivers; Healthcare professionals
资金
- Innovative Medicines Initiative 2 Joint Undertaking [116020]
- European Union
- EFPIA
Introduction Clinical trials involving patients with Alzheimer's disease (AD) continue to try to identify disease-modifying treatments. Although trials are designed to meet regulatory and registration requirements, many do not measure outcomes of the disease most relevant to key stakeholders. Methods A systematic review sought research that elicited information from people with AD, their caregivers, and health-care professionals on which outcomes of the disease were important. Studies published in any language between 2008 and 2017 were included. Results Participants in 34 studies described 32 outcomes of AD. These included clinical (memory, mental health), practical (ability to undertake activities of daily living, access to health information), and personal (desire for patient autonomy, maintenance of identity) outcomes of the disease. Discussion Evidence elicited directly from the people most affected by AD reveals a range of disease outcomes that are relevant to them but are not commonly captured in clinical trials of new treatments.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据